Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

NCT01350401 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of enrollment

Conditions

Melanoma

Interventions

GENETIC: Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T

Sponsor

Adaptimmune